Sfoglia per AUTORE
RUBIO J
Collezione ASL Biella

  

Items : 2

Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database in Journal of Clinical Oncology

2020
ASL Biella

Francini E; Montagnani F; Nuzzo PV; Gonzalez-Velez M; Alimohamed NS; Cigliola A; Moreno I; Rubio J; Crivelli F; Shaw G; Petrioli R; Bengala C; Francini G; Foncillas JG; Sweeney C; Higano CS; Bryce AH; Harshman LC; Lee-Ying R; Heng DYC;

Efficacy of bone resorption inhibitors (BRI) + abiraterone acetate + prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry in Journal of Clinical Oncology

2019
ASL Biella

Francini E; Montagnani F; Vitale NP; Alimohamed NS; Candilejo IM; Rosellini P; Gonzalez-Velez M; Rubio J; Zhang L; Shaw G; Crivelli F; Petrioli R; Bengala C; Francini G; Foncillas JG; Bryce AH; Sweeney C; Harshman LC; Lee-Ying R; Heng DYC;